Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors

Journal of Nuclear Medicine

Volumn 54, Issue 3, 2013, Pages 364-372

  Wild, Damian ^a,b   Bomanji, Jamshed B ^a   Benkert, Pascal ^b   Maecke, Helmut ^b   Ell, Peter J ^a   Reubi, Jean Claude ^c   Caplin, Martyn E ^d  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

68Ga; DOTA NOC; Neuroendocrine tumors; PET CT; Somatostatin receptor targeting

Indexed keywords

DOTANOC GA 68; DOTATATE GA 68; GADOTERATE MEGLUMINE; IOHEXOL; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG; 68GA DOTANOC; 68GA DOTATATE; 68GA-DOTANOC; 68GA-DOTATATE; DIAGNOSTIC AGENT; GALLIUM; ORGANOMETALLIC COMPOUND; SOMATOSTATIN RECEPTOR;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER GRADING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DRUG SPECIFICITY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIVARIATE ANALYSIS; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIGESTIVE SYSTEM TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; DIGESTIVE SYSTEM NEOPLASMS; FEMALE; GALLIUM RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN;

MLCS; MLOWN;

EID: 84874875874     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.111724     Document Type: Article

References (36)

1. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30:781-793. (Pubitemid 36612963)
2. Kwekkeboom DJ, Krenning EP, Scheidhauer K, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with 111In-pentetreotide. Neuroendocrinology. 2009;90: 184-189.
3. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-2130.
4. Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90YDOTA]- TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29: 2416-2423.
5. 123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20: 716-731. (Pubitemid 23284773)
6. Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30:1338-1347. (Pubitemid 37247950)
7. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging. 2005;32:724. (Pubitemid 40897499)
8. Antunes P, Ginj M, Zhang H, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34:982-993. (Pubitemid 46919547)
9. Asnacios A, Courbon F, Rochaix P, et al. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol. 2008;26:963- 970. (Pubitemid 351398091)
10. 68Ga-DOTA-Tyr3- octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-518. (Pubitemid 47571404)
11. 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617-1626. (Pubitemid 47476920)
12. 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010;51:875-882.
13. Ambrosini V, Tomassetti P, Franchi R, Fanti S. Imaging of NETs with PET radiopharmaceuticals. Q J Nucl Med Mol Imaging. 2010;54:16-23.
14. 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52:1864-1870.
15. 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39:1271- 1277.
16. 68Ga for medical application. J Nucl Med. 2007;48:1741-1748. (Pubitemid 47572722)
17. 68Ga-DOTATATE in disease-free patients. Nucl Med Commun. 2010;31:1025-1032.
18. 18F-FDG. Cancer. 2008;112:2447-2455.
19. Blaker H. Confidence curves and improved exact confidence intervals for discrete distributions. Can J Stat. 2000;28:783-798. (Pubitemid 33241221)
20. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998;17:873- 890. (Pubitemid 28185166)
21. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707-712.
22. 68Ga] DOTATOC-PET/CT and whole-body MRI in staging of neuroendocrine tumors [abstract]. Cancer Imaging. 2011;11(spec no. A):S38-S39.
23. 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2009;36: 765-770.
24. Mikkaichi T, Suzuki T, Tanemoto M, Ito S, Abe T. The organic anion transporter (OATP) family. Drug Metab Pharmacokinet. 2004;19:171-179.
25. 68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med Mol Imaging. 2011;38:1224-1236.
26. Epelbaum J, Bertherat J, Prevost G, et al. Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal, and malignant pheochromocytomas. J Clin Endocrinol Metab. 1995;80: 1837-1844.
27. Kubota A, Yamada Y, Kagimoto S, et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest. 1994;93: 1321-1325. (Pubitemid 24087192)
28. Unger N, Serdiuk I, Sheu SY, et al. Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours. Clin Endocrinol (Oxf). 2008;68:850-857. (Pubitemid 351703940)
29. Lupp A, Nagel F, Doll C, et al. Reassessment of sst(3) somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-5. Neuroendocrinology. March 13, 2012 [Epub ahead of print].
30. Reubi JC, Kappeler A, Waser B, Schonbrunn A, Laissue J. Immunohistochemical localization of somatostatin receptor sst2A in human pancreatic islets. J Clin Endocrinol Metab. 1998;83:3746-3749. (Pubitemid 28500920)
31. Gugger M, Waser B, Kappeler A, Schonbrunn A, Reubi JC. Cellular detection of sst2A receptors in human gastrointestinal tissue. Gut. 2004;53: 1431-1436. (Pubitemid 39265261)
32. Reubi JC, Waser B, Horisberger U, et al. In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue. Blood. 1993;82:2143-2151. (Pubitemid 23293998)
33. Ben-Shlomo A, Melmed S. Pituitary somatostatin receptor signaling. Trends Endocrinol Metab. 2010;21:123-133.
34. Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibanski A. Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab. 1995;80:1386-1392.
35. 68Ga- DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT. J Nucl Med. 2011;52:886- 890.
36. 68Ga-labeled peptide solutions. J Radioanal Nucl Chem. 2010;283:753-756.